Herpes zoster virus of shingles
About us We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
Read morePress releases
- IAS 2019: ViiV Healthcare showcasing innovation in HIV science
- GSK announces positive headline results in Phase 3 PRIMA study of ZEJULA (niraparib) for patients with ovarian cancer in the first line maintenance setting
- ViiV Healthcare announces phase III study meets primary endpoint, demonstrating the ability to control HIV-1 with a 2-drug regimen of dolutegravir plus lamivudine in virally suppressed patients switching from a TAF-containing, 3-drug regimen
Tweets from GSK
-
GSK @GSK
Together with @ViiVHC, we're excited to be joining over 6,000 people from more than 140 countries at the 10th IAS Conference on #HIV Science next week in Mexico City. #IAS2019 #HIVResearch @IAS_conference twitter.com/ViiVHC/status/…
about 9 hours ago
-
GSK @GSK
Phil Thomson, President, Global Affairs, spoke alongside @DFID_UK, @GlobalFund, @savechildrenuk hosted by @MattHancock and @BritainLeads in Parliament on GSK's commitment to a #GlobalHealth strategy of investing in R&D for HIV, TB & malaria. Find out more: gsk.to/2lhwCK5
about 11 hours ago
-
GSK @GSK
ViiV Healthcare are heading to Mexico for #IAS2019 where they’ll be discussing all the latest in #HIV/#AIDS research. Follow @ViiVHC for live updates! twitter.com/ViiVHC/status/…
about 1 day ago
